Friday 6th October 2017, 11:00am
Synpromics is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards.
The company, recently relocated to Roslin Innovation Centre, was nominated on the strength of being the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design.
The OBN Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry, including emerging to late-stage R&D companies as well as life science investors.
The Awards cover Biotech, Medtech, Synthetic Biology and Digital Health.
"We could not be happier with the outcome of last night’s Awards. This accolade is testament to the significant progress we have made over the past year, in growing our business by expanding the number of partnerships that we have with top pharma and biotech companies and significantly expanding our team."
Michael Roberts, Founder & CSO of SynpromicsOBN is the Membership organisation supporting and bringing together the UK’s innovative life sciences companies, corporate partners and investors.
For further information about Synpromics Ltd, please contact:
Corporate:
Dr Michael Roberts, CSO
Synpromics Ltd
T: +44 (0)131 651 9667
E: info@synpromics.com
PR:
Deborah Cockerill / Emma Pickup
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: synpromics@sciad.com
Roslin Innovation Centre
The University of Edinburgh
Easter Bush Campus
Midlothian EH25 9RG
